Kurt Zinn
Hickman Family Endowed Chair, Professor Michigan State University
- East Lansing MI
Kurt Zinn develops molecular imaging approaches for cancer diagnosis, treatment monitoring, and therapy
Media
Biography
Industry Expertise
Areas of Expertise
Accomplishments
Distinguished Investigator Award
2015-02-01
Academy of Radiology Research
Education
University of Missouri
Ph.D.
Biochemistry
1992
University of Missouri
M.S.
Chemistry
1986
University of Missouri
D.V.M
1996
University of Missouri
B.A.
Chemistry
1981
News
A targeted and personalized approach to fighting cancer
MSU Today online
2022-06-22
Michigan State University is one of the top 100 research universities in the world and a member of the prestigious Association of American Universities, widely regarded as among the top research-intensive institutions in North America. The following story highlights one of the many examples of MSU’s research excellence and innovation.
Testing a new way to tackle cancer
MSU Today online
2021-04-02
A potential new weapon against cancer is entering the first phase of clinical trials thanks to a collaboration between Spectrum Health, the Lansing-based company Niowave and Michigan State University.
MSU’s Kurt Zinn, a professor of biomedical engineering, radiology and small animal clinical sciences, is leading the effort to validate an innovative radiotherapy as part of a safe, more effective and potentially less costly treatment for bladder cancer.
Journal Articles
Clinical Scaleup of Humanized AnnA1 Antibody Yielded Unexpected High Reticuloendothelial (RES) Uptake in Mice
AntibodiesLu Lucy Xu, Satyendra Kumar Singh, Chelsea Nayback, Abdullah Metebi, Dalen Agnew, Tim Buss, Jan Schnitzer and Kurt R. Zinn
2025-02-06
A mouse antibody directed against truncated Annexin A1 showed high tumor retention in pre-clinical cancer models and was approved by the National Cancer Institute Experimental Therapeutics (NExT) program for humanization and large batch cGMP production for toxicology and clinical trials. In this process, a contractor for Leidos accidentally produced a mutated version of humanized AnnA1 (hAnnA1-mut) with a single nucleotide deletion in the terminal Fc coding region that increased the translated size by eight amino acids with random alterations in the final twenty-four amino acids.
Comparisons of 3D printed materials for biomedical imaging applications
Science and Technology of Advanced MaterialsMitchell A. Gabalski, Kylie R. Smith, Jeremy Hix & Kurt R. Zinn
2023-11-14
In biomedical imaging, it is desirable that custom-made accessories for restraint, anesthesia, and monitoring can be easily cleaned and not interfere with the imaging quality or analyses. With the rise of 3D printing as a form of rapid prototyping or manufacturing for imaging tools and accessories, it is important to understand which printable materials are durable and not likely to interfere with imaging applications. Here, 15 3D printable materials were evaluated for radiodensity, optical properties, simulated wear, and capacity for repeated cleaning and disinfection. Materials that were durable, easily cleaned, and not expected to interfere with CT, PET, or optical imaging applications were identified.
Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics
PharmaceuticsNathan Kauffman, James Morrison, Kevin O’Brien, Jinda Fan and Kurt R. Zinn
2023-04-04
A paradigm shift is underway in cancer diagnosis and therapy using radioactivity-based agents called radiopharmaceuticals. In the new strategy, diagnostic imaging measures the tumor uptake of radioactive agent “X” in a patient’s specific cancer, and if uptake metrics are realized, the patient can be selected for therapy with radioactive agent “Y”. The X and Y represent different radioisotopes that are optimized for each application.
